Editor’s note

  • Abiding by the rules

    The debate about replacing PET packaging with glass as packaging material for pharmaceuticals is reaching yet another milestone as the matter is due to come...

  • Opportunities amidst challenges

    MSF’s seven-year-old appeal campaign to reduce flu vaccine prices has finally borne fruit

  • Reviving APIs

    Even as Indian pharmaceutical companies pursue aggressive plans for global expansion, there are deep challenges in the domestic market

  • Thriving through change

    A recently released analysis of the global courier industry from 2010-2021, shows that the pharmaceutical sector accounts for just seven per cent of the sector's global...

  • Testing the new FDI norms

    The Modi government’s reforms have tinkered with FDI norms twice, first in November 2015 and more recently in June this year

  • Turning threat into opportunity

    It is human nature to perceive change as a threat. But turning this threat into an opportunity is a crucial skill

  • Back to the basics

    After taking a beating from overseas regulators for the past few years, analysts are finally sounding marginally cautious about the fortunes of pharma companies in...

  • Redrawing the Lakshman rekha

    A national IPR policy, new FDI norms, a possible revamp of the Drugs & Cosmetics Act, Brexit: the pharma sector in India has a lot...

  • Betting big on M&As

    Dr Reddy's Laboratories' June 11 announcement that it had entered into an agreement with Teva and Allergan to buy eight Abbreviated New Drug Applications (ANDAs)...

  • Moving up the green ladder

    As the Modi Government launches its second anniversary celebration on May 26, the BJP will be organising 200 odd events over a fortnight, accompanied by...

  • Embracing quality as an opportunity

    Concerned with declining pharma exports in the recent past, the Ministry of Commerce & Industry has tried to burnish the brand image of India's pharmaceutical...

  • To switch or not to switch …

    A notice dated March 30 from the Drug Controller General (India) asking for ‘science-based suggestions/ comments’ on the pros and cons of replacing animal-based gelatin capsules...

  • Quality consciousness: A pre-requisite to progress

    Manufacturing quality has now become probably the single most important concern in the boardrooms of pharmaceutical companies in India

  • Weeding out the bad FDCs

    The fixed dose combination (FDC) issue has been a contentious one for years and on March 10 came back to haunt pharma companies in India

  • Once again, nothing much for pharma

    In his third budget, Finance Minister Arun Jaitley has taken one more shot at a balancing act between maintaining fiscal discipline and loosening the purse...

  • Public health: In need of Nari Shakti

    As we mark yet another Women’s Day this March, here are some sobering words from Sanghita Bhattacharyya, Senior Public Health Specialist at the Public Health...

  • Revival mantras for MSMEs

    Precious things come in small packages (think diamonds)

  • Acche Din Kab Aayenge?

    All eyes are once again on India's Finance Minister Arun Jaitley as he prepares to present the Modi Government's second full budget

  • Online pharmacies both game changers and troublemakers

    I’d hazard a guess that there is hardly anyone who is not a user of e-commerce platforms to ease the daily grind

  • WL dims Sun’s shine … a bit

    A new year brings with it new hope but all indications are that 2016 is going to be a mixed bag for the pharmaceutical industry

  • Of laws and flaws

    Could New Jersey Superior Court's decision this October be a wake up call for Indian companies with global ambitions

  • Sifting the trends into 2016

    If the latest edition of the Antal Global Snapshot (AGS) on annual global hiring and firing trends is any indicator, hiring in India’s pharmaceutical industry...

  • Will new IP policy ensure Sabka Vikas?

    In our last issue, we highlighted Swati Spentose’s quiet rise to become a Rs 40-crore speciality API manufacturer

  • Finding the hidden gems

    Vishal Jajodia could sign up as a poster boy for Prime Minister Narendra Modi's Make In India campaign

  • Balancing the scales

    Besides the balanced reasoning within the Delhi HC judgement, it is the SC's intervention which could see this case go down as a major milestone

  • Mainstreaming AYUSH

    The last month saw a major milestone in the patent versus patient debate

  • Playing for high stakes

    According to the latest data from the India Brand Equity Foundation (IBEF), the Indian domestic pharma market ended FY15 with a growth of 12 per...